Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - rizatriptan benzoate - oral lyophilisate - 10 milligram(s) - selective serotonin (5ht1) agonists; rizatriptan

Kanada - Ingliż - Health Canada

mint pharmaceuticals inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 5mg - rizatriptan (rizatriptan benzoate) 5mg - selective serotonin agonists

Kanada - Ingliż - Health Canada

mint pharmaceuticals inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 10mg - rizatriptan (rizatriptan benzoate) 10mg - selective serotonin agonists

Kanada - Ingliż - Health Canada

vanc pharmaceuticals inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 5mg - rizatriptan (rizatriptan benzoate) 5mg - selective serotonin agonists

Kanada - Ingliż - Health Canada

vanc pharmaceuticals inc - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 10mg - rizatriptan (rizatriptan benzoate) 10mg - selective serotonin agonists

Kanada - Ingliż - Health Canada

cellchem pharmaceuticals inc. - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 5mg - rizatriptan (rizatriptan benzoate) 5mg - selective serotonin agonists

Kanada - Ingliż - Health Canada

cellchem pharmaceuticals inc. - rizatriptan (rizatriptan benzoate) - tablet (orally disintegrating) - 10mg - rizatriptan (rizatriptan benzoate) 10mg - selective serotonin agonists

Stati Uniti - Ingliż - NLM (National Library of Medicine)

sandoz inc - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: naratriptan is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with use of naratriptan tablets in pregnant women. data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have documented outcomes in women exposed to naratriptan during pregnancy; however, due to small sample sizes, no definitive conclusions can be drawn regarding the risk of birth defects following exposure to naratriptan [see data]. in animal studies, naratriptan produced developmental toxicity (including embryolethality and fetal abnormalities) when administered to pregnant rats and rabbits. the lowest doses producing evidence of developmental toxicity in animals were associated with plasma exposures 2.5 (rabbit) to 11 (rat) times that in humans at the maximum recommended daily dose (mrdd) [see data]. in the u.s. genera

Stati Uniti - Ingliż - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1) ] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway d

Stati Uniti - Ingliż - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - sumatriptan succinate (unii: j8bdz68989) (sumatriptan - unii:8r78f6l9vo) - sumatriptan 25 mg - sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see contraindications ). safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. sumatriptan tablets should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. in addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptane tablets. ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort, vasospastic forms of angina such as the prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. cerebrovascular syndromes include, but are not limited to, stro